Susquehanna International Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-12,901
Closed -$142K 10184
2017
Q2
$142K Buy
+12,901
New +$129K ﹤0.01% 8523
2017
Q1
Sell
-91,166
Closed -$985K 10694
2016
Q4
$985K Buy
+91,166
New +$912K ﹤0.01% 5567
2016
Q2
Sell
-26,233
Closed -$344K 9839
2016
Q1
$289K Sell
26,233
-5,095
-16% -$45.3K ﹤0.01% 7323
2015
Q4
$288K Sell
31,328
-64,855
-67% -$543K ﹤0.01% 7764
2015
Q3
$668K Sell
96,183
-99,027
-51% -$848K ﹤0.01% 6558
2015
Q2
$1.92M Buy
195,210
+75,471
+63% +$687K ﹤0.01% 4807
2015
Q1
$1.06M Sell
119,739
-53,032
-31% -$422K ﹤0.01% 5650
2014
Q4
$1.51M Buy
172,771
+100,571
+139% +$814K ﹤0.01% 5017
2014
Q3
$497K Buy
72,200
+22,056
+44% +$132K ﹤0.01% 7226
2014
Q2
$264K Buy
50,144
+16,513
+49% +$80.4K ﹤0.01% 8600
2014
Q1
$153K Sell
33,631
-16,310
-33% -$78.8K ﹤0.01% 8407
2013
Q4
$252K Sell
49,941
-5,131
-9% -$24.7K ﹤0.01% 7867
2013
Q3
$279K Buy
+55,072
New +$307K ﹤0.01% 7317

Other funds holding SCLN

Susquehanna International Group's SCLN Position: Q3 2017 in Review

Susquehanna International Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 12,901 shares — an estimated $142K sold.

Susquehanna International Group first reported a position in SCLN in Q3 2013 and held it in 13 quarters. The position peaked at $1.92M in Q2 2015. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Susquehanna International Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Susquehanna International Group sold 12,901 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $142K.
  • Susquehanna International Group first reported a position in Sciclone Pharmaceuticals Inc in Q3 2013 and held it in 13 quarters.
  • Susquehanna International Group's Sciclone Pharmaceuticals Inc position peaked at $1.92M in Q2 2015.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Susquehanna International Group's 13F filing for Q3 2017, filed 14 Nov 2017.